Guided therapy selection in rheumatoid arthritis using a molecular signature response classifier: an assessment of budget impact and clinical utility

BACKGROUND: Patients with moderate to severe rheumatoid arthritis (RA) can be treated with a range of targeted therapies following inadequate response to conventional synthetic disease-modifying antirheumatic drugs such as methotrexate. Whereas clinical practice guidelines provide no formal recommen...

Descripción completa

Detalles Bibliográficos
Autores principales: Arnell, Christopher, Bergman, Martin, Basu, Dhiman, Kenney, James T, Withers, Johanna B, Logan, Jennifer, Harashima, Jeraldine Lim, Connolly-Strong, Erin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394192/
https://www.ncbi.nlm.nih.gov/pubmed/34669487
http://dx.doi.org/10.18553/jmcp.2021.21120

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394192/
https://www.ncbi.nlm.nih.gov/pubmed/34669487
http://dx.doi.org/10.18553/jmcp.2021.21120

Ejemplares similares